Sun Pharma and Bayer Sign Pact To Sell Drug For Chronic Kidney Disease

Sun Pharma announced a collaboration with Bayer to market a medication for the treatment of chronic kidney disease and other conditions. Under the terms of the deal, Bayer granted Sun Pharma non-exclusive rights to market and distribute a second Finerenone medication under the brand name Lyvelsa.

Finerenone was first launched by Bayer under the brand name Kerendia in 2022, as per economic times.

"This partnership underscores our commitment to make innovative medicines available to patients in India," Sun Pharma India Business CEO Kirti Ganorkar said in a statement.

Bayer's Pharmaceuticals South Asia Country Division Head Shweta Rai stated that the introduction of a second brand of Finerenone in India, through a collaboration with Sun Pharma, advances the company's mission to making healthcare accessible to as many patients as possible.

"India has a high incidence of diabetes and associated renal and cardiac conditions. The true value of innovations like Finerenone can only be fully realised after they reach all deserving patients," she added.

Finerenone, a patented drug, is used to minimize the risk of long-term eGFR decline, end-stage renal disease, cardiovascular death, non-fatal myocardial infarction, and heart failure hospitalization in adult patients with chronic kidney disease and type 2 diabetes mellitus.

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical firm located in Mumbai that develops and sells pharmaceutical formulations and active pharmaceutical ingredients in over 100 countries worldwide.